D.E. Shaw & Co
CRVS icon

D.E. Shaw & Co’s Corvus Pharmaceuticals CRVS Stock Holding History

D.E. Shaw & Co’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,915
Closed -$500K – 4625
2025
Q4 		$500K Buy
64,915
+39,340
+154% +$310K ﹤0.01% 3930
2025
Q3 		$188K Buy
+25,575
New +$131K ﹤0.01% 4296

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co's CRVS Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 64,915 shares — an estimated $500K sold.

D.E. Shaw & Co first reported a position in CRVS in Q3 2025 and held it in 2 quarters. The position peaked at $500K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 64,915 Corvus Pharmaceuticals shares in Q1 2026, an estimated $500K.
  • D.E. Shaw & Co first reported a position in Corvus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • D.E. Shaw & Co's Corvus Pharmaceuticals position peaked at $500K in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.